268 related articles for article (PubMed ID: 12663719)
41. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313
[TBL] [Abstract][Full Text] [Related]
42. Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.
Sumpter K; Harper-Wynne C; Cunningham D; Gillbanks A; Norman AR; Hill M
Clin Oncol (R Coll Radiol); 2003 Aug; 15(5):221-6. PubMed ID: 12924449
[TBL] [Abstract][Full Text] [Related]
43. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
44. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Kim ST; Hong YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Lee JW; Jo SJ; Park YS
BMC Cancer; 2014 Nov; 14():883. PubMed ID: 25424120
[TBL] [Abstract][Full Text] [Related]
45. Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Cassinello J; Alvarez JV; López MJ; Pujol E; Colmenarejo A; Segovia F; Marcos F; Filipovich E; Arcediano A; Castro IG
Clin Colorectal Cancer; 2006 Mar; 5(6):429-35. PubMed ID: 16635282
[TBL] [Abstract][Full Text] [Related]
46. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Twelves CJ; Butts CA; Cassidy J; Conroy T; Braud Fd; Diaz-Rubio E; Tabernero JM; Schoffski P; Figer A; Brunet R; Grossmann J; Sobrero AF; Van Cutsem EJ
Clin Colorectal Cancer; 2005 Jul; 5(2):101-7. PubMed ID: 16098250
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R
J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087
[TBL] [Abstract][Full Text] [Related]
48. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.
Feliu J; Salud A; Escudero P; Lopez-Gómez L; Bolaños M; Galán A; Vicent JM; Yubero A; Losa F; De Castro J; de Mon MA; Casado E; González-Barón M
Br J Cancer; 2006 Apr; 94(7):969-75. PubMed ID: 16552438
[TBL] [Abstract][Full Text] [Related]
49. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
50. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B
Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035
[TBL] [Abstract][Full Text] [Related]
51. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
Hwang IG; Ji JH; Kang JH; Lee HR; Lee HY; Chi KC; Park SW; Lee SJ; Kim ST; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
J Geriatr Oncol; 2017 May; 8(3):170-175. PubMed ID: 28119041
[TBL] [Abstract][Full Text] [Related]
52. A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Gelibter AJ; Gamucci T; Pollera CF; Di Costanzo F; Nuzzo C; Gabriele A; Signorelli C; Gasperoni S; Ferraresi V; Giannarelli D; Cognetti F; Zeuli M
Curr Med Res Opin; 2007 Sep; 23(9):2117-23. PubMed ID: 17651538
[TBL] [Abstract][Full Text] [Related]
53. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
54. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
55. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
Farid M; Chowbay B; Chen X; Tan SH; Ramasamy S; Koo WH; Toh HC; Choo SP; Ong SY
Cancer Chemother Pharmacol; 2012 Jul; 70(1):141-50. PubMed ID: 22648745
[TBL] [Abstract][Full Text] [Related]
56. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Rivera F; Massutí B; Salcedo M; Sastre J; Martínez Galán J; Valladares-Ayerbes M; Serrano R; García de Paredes ML; Manzano JL; Galán M; Alsina M; Yuste Izquierdo AL; López C; Díaz-Rubio E; Conde V; Reboredo M; Cano MT; Pachón V; Aranda E
Cancer Chemother Pharmacol; 2015 Feb; 75(2):319-24. PubMed ID: 25491381
[TBL] [Abstract][Full Text] [Related]
57. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
Borner MM; Bernhard J; Dietrich D; Popescu R; Wernli M; Saletti P; Rauch D; Herrmann R; Koeberle D; Honegger H; Brauchli P; Lanz D; Roth AD;
Ann Oncol; 2005 Feb; 16(2):282-8. PubMed ID: 15668285
[TBL] [Abstract][Full Text] [Related]
58. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
59. A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Ogata Y; Shimokawa M; Tanaka T; Emi Y; Oki E; Saeki H; Sadanaga N; Kusumoto T; Touyama T; Kimura M; Baba H; Akagi Y; Shirouzu K; Maehara Y;
Int J Clin Oncol; 2016 Apr; 21(2):335-343. PubMed ID: 26338269
[TBL] [Abstract][Full Text] [Related]
60. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Tol J; Koopman M; Rodenburg CJ; Cats A; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; Mol L; Antonini NF; Punt CJ
Ann Oncol; 2008 Apr; 19(4):734-8. PubMed ID: 18272912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]